Have your own idea? Try our Stock Screener
U.S. Biotech Industry Analysis
UpdatedMay 25, 2025
DataAggregated Company Financials
Companies569
- 7D1.1%
- 3M-10.8%
- 1Y-12.9%
- YTD-6.0%
In the last week, the Biotech industry is up 1.1%, with Gilead Sciences up 4.8%. In the past year, the industry is down 13%. As for the next few years, earnings are expected to grow by 24% per annum.
Industry Valuation and Performance
Has the U.S. Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sun, 25 May 2025 | US$907.6b | US$155.9b | -US$24,118,382,442.03 | 15.6x | -37.6x | 5.8x |
| Tue, 22 Apr 2025 | US$757.2b | US$119.3b | -US$36,503,635,360.22 | 19.1x | -20.7x | 6.3x |
| Thu, 20 Mar 2025 | US$833.1b | US$118.4b | -US$37,426,956,446.75 | 20.1x | -22.3x | 7x |
| Sat, 15 Feb 2025 | US$843.4b | US$116.6b | -US$36,838,403,221.21 | 17.6x | -22.9x | 7.2x |
| Mon, 13 Jan 2025 | US$947.7b | US$149.4b | -US$26,263,014,335.71 | 16.6x | -36.1x | 6.3x |
| Wed, 11 Dec 2024 | US$1.0t | US$150.0b | -US$26,535,944,620.11 | 17.9x | -39x | 6.9x |
| Fri, 08 Nov 2024 | US$1.1t | US$149.1b | -US$31,021,469,881.25 | 17x | -35.4x | 7.4x |
| Sun, 06 Oct 2024 | US$889.8b | US$113.1b | -US$35,952,253,973.77 | 22x | -24.8x | 7.9x |
| Tue, 03 Sep 2024 | US$909.4b | US$113.1b | -US$35,704,251,292.69 | 24x | -25.5x | 8x |
| Thu, 01 Aug 2024 | US$1.2t | US$165.1b | -US$29,392,630,542.96 | 30.2x | -41.8x | 7.4x |
| Sat, 29 Jun 2024 | US$1.1t | US$164.4b | -US$28,157,592,218.37 | 28.5x | -40.7x | 7x |
| Mon, 27 May 2024 | US$1.1t | US$164.6b | -US$26,653,350,594.72 | 23.8x | -42.2x | 6.8x |
| Wed, 24 Apr 2024 | US$1.1t | US$164.3b | -US$23,439,543,461.97 | 20.4x | -46.7x | 6.7x |
| Fri, 22 Mar 2024 | US$1.2t | US$164.3b | -US$23,898,885,613.21 | 21.6x | -48.8x | 7.1x |
| Sun, 18 Feb 2024 | US$1.2t | US$169.1b | -US$20,519,191,458.58 | 15.7x | -56.9x | 6.9x |
| Tue, 16 Jan 2024 | US$1.4t | US$204.8b | -US$22,498,525,782.00 | 18.8x | -63.9x | 7x |
| Thu, 14 Dec 2023 | US$1.3t | US$204.7b | -US$22,099,611,280.00 | 19.6x | -59.9x | 6.5x |
| Sat, 11 Nov 2023 | US$1.2t | US$204.5b | -US$22,053,784,561.00 | 18.5x | -54.1x | 5.8x |
| Mon, 09 Oct 2023 | US$1.3t | US$207.4b | -US$13,060,168,797.00 | 17.2x | -96.4x | 6.1x |
| Wed, 06 Sep 2023 | US$1.3t | US$207.5b | -US$12,513,012,217.00 | 17.2x | -102x | 6.2x |
| Fri, 04 Aug 2023 | US$1.1t | US$183.2b | -US$17,641,388,597.00 | 14.5x | -64.3x | 6.2x |
| Sun, 02 Jul 2023 | US$1.1t | US$186.2b | -US$16,042,400,813.00 | 13.7x | -70x | 6x |
| Tue, 30 May 2023 | US$1.1t | US$185.9b | -US$16,045,777,796.00 | 11.2x | -69.9x | 6x |
| Thu, 27 Apr 2023 | US$1.2t | US$198.5b | -US$3,096,107,692.00 | 12.8x | -375.3x | 5.9x |
| Sat, 25 Mar 2023 | US$1.1t | US$199.3b | -US$3,645,756,952.00 | 13.4x | -310.8x | 5.7x |
| Mon, 20 Feb 2023 | US$1.2t | US$202.6b | -US$64,851,937.00 | 16.5x | -17789.6x | 5.7x |
| Wed, 18 Jan 2023 | US$1.2t | US$203.6b | US$1.7b | 14.6x | 683.1x | 5.8x |
| Fri, 16 Dec 2022 | US$1.2t | US$203.3b | US$1.6b | 14.5x | 734.9x | 5.7x |
| Sun, 13 Nov 2022 | US$1.1t | US$202.2b | US$1.1b | 14.6x | 1045.5x | 5.5x |
| Tue, 11 Oct 2022 | US$1.0t | US$205.9b | US$5.4b | 14.9x | 192.3x | 5x |
| Thu, 08 Sep 2022 | US$1.0t | US$206.1b | US$6.0b | 14.5x | 169.1x | 5x |
| Sat, 06 Aug 2022 | US$1.1t | US$211.4b | US$8.8b | 16.7x | 125.7x | 5.3x |
| Mon, 04 Jul 2022 | US$1.1t | US$212.1b | US$11.0b | 15.8x | 95.4x | 5x |
| Wed, 01 Jun 2022 | US$1.0t | US$212.7b | US$11.2b | 15.2x | 89.5x | 4.7x |
Price to Earnings Ratio
89.5x
Current Industry PE
- Investors are relatively neutral on the American Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PS ratio of 6.3x.
Past Earnings Growth
- Total earnings for the Biotechs industry have declined over the last three years, with the industry now making a loss overall.
- Revenues have also declined 9.8% per year, which is driving profits down.
Industry Trends
Which industries have driven the changes within the U.S. Healthcare industry?
| US Market | -2.65% | |
| Healthcare | -2.20% | |
| Biotech | 1.11% | |
| Biotech | 1.11% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| GILD Gilead Sciences | US$107.37 | 4.8% +US$6.1b | 63.5% | PE22.4x | |
| ONC BeiGene | US$241.43 | 5.7% +US$3.9b | 58.1% | PS6.8x | |
| SMMT Summit Therapeutics | US$25.85 | 8.3% +US$1.5b | 664.8% | PB55.8x | |
| BNTX BioNTech | US$98.68 | 6.4% +US$1.4b | 1.8% | PS7.6x | |
| MRUS Merus | US$55.14 | 32.7% +US$939.9m | -8.1% | PS69.7x |